Top 10 Asian Companies To Buy Right Now: Amarin Corporation PLC(AMRN)
Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. Its lead product candidate includes AMR101, a prescription grade omega-3 fatty acid, which is in second Phase III clinical trial for the treatment of high triglyceride levels in statin-treated patients who have mixed dyslipidemia. The company, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.
Advisors' Opinion:- [By Sean Williams]
Over the previous two days, we've looked at chronic weight management company VIVUS (NASDAQ: VVUS ) , and advanced prostate cancer treatment provider Dendreon (NASDAQ: DNDN ) , as two companies that missed the ball with their marketing and/or pricing. Both companies, I feel, would do well to seek out an experienced marketing partner to help increase product sales, and share in the costs of that marketing and production.
Today, in the third and final installment of three biotech companies that could desperately use a marketing partner, I would like to look more closely at Amarin (NASDAQ: AMRN ) , and discuss why I feel it would be wise to find a big pharma friend. - [By Sean Williams]
Now what: Omthera shareholders certainly made out like bandits today, just a month after the company went public. While it's certainly a boost for Omthera with the financial backing of AstraZeneca, it's a crushing blow to Amarin (NASDAQ: AMRN ) and its FDA-approved fish oil treatment Vascepa. Amarin has long been thought to be the buyout candidate based on its triglyceride-lowering fish oil treatment, yet Omthera, at roughly 45% of Amarin's market value, garnered the interest from big pharma. Worse yet, AstraZeneca can kick in its marketing expertise if Epanova is eventually approved. Today is certainly a case of one company's pain b! eing another's gain!
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-asian-companies-to-buy-right-now.html
No comments:
Post a Comment